Document Detail


Inadequate control of heart rate in patients with stable angina: results from the European heart survey.
MedLine Citation:
PMID:  20354044     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To examine resting heart rate (HR) in a population presenting with stable angina in relation to prior and subsequent pharmacological treatment, comorbid conditions and clinical outcome. METHODS AND RESULTS: The European Heart Survey was a prospective, observational, cohort study of 3779 patients with stable angina newly presenting to cardiology services. Mean baseline resting HR was 73 beats/min (bpm) and 52.3% of patients had a baseline HR > 70 bpm. Over half of patients were on no chronotropic medication at baseline. Patients with chronic respiratory disease or diabetes had higher resting HRs (75-76 bpm), and were more likely to have been receiving calcium channel blockers at baseline assessment. Overall, beta-blockers were the most common treatment administered following cardiologist assessment, but were used less frequently in patients with chronic respiratory disease and diabetes, and the dosages used were less than that found to be effective in clinical trials. Mean daily doses of metoprolol, bisoprolol, carvedilol, and atenolol were 75 mg, 6 mg, 19 mg and 55 mg, respectively. Higher HR at baseline was associated with higher rates of cardiovascular mortality and hospitalisation for heart failure. CONCLUSION: Control of ischaemic symptoms through heart rate modification in patients with angina is currently inadequate, both by primary referring physicians and cardiologists. Given the adverse outcome associated with higher resting heart rates in this as in other studies, and the availability of specific HR reducing strategies, attention should be given to achieving optimal HR control.
Authors:
Caroline A Daly; Felicity Clemens; Jose L Lopez Sendon; Luigi Tavazzi; Eric Boersma; Nicolas Danchin; François Delahaye; Anselm Gitt; Desmond Julian; David Mulcahy; Witold Ruzyllo; Kristian Thygesen; Freek Verheugt; Kim M Fox;
Related Documents :
12798574 - Bedside b-type natriuretic peptide in the emergency diagnosis of heart failure with red...
20691834 - Prognostic value of osteoprotegerin in chronic heart failure: the gissi-hf trial.
17719334 - Diagnostic usefulness and prognostic implications of the mitral e/e' ratio in patients ...
12928654 - Outcome of symptomatic patients undergoing extracardiac fontan conversion and cryoablat...
18018754 - The patients with severe chronic obstructive pulmonary disease and chronic respiratory ...
17078954 - A review of traumatic airway injuries: potential implications for airway assessment and...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Postgraduate medical journal     Volume:  86     ISSN:  1469-0756     ISO Abbreviation:  Postgrad Med J     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-31     Completed Date:  2010-10-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234135     Medline TA:  Postgrad Med J     Country:  England    
Other Details:
Languages:  eng     Pagination:  212-7     Citation Subset:  IM    
Affiliation:
St James's Hospital, Dublin 8, Ireland. cadaly@stjames.ie
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Angina Pectoris / complications,  drug therapy,  physiopathology*
Anti-Arrhythmia Agents / therapeutic use*
Arrhythmias, Cardiac / complications,  drug therapy*
Diabetes Complications / complications
Female
Heart Rate* / physiology
Humans
Hypertension / complications
Male
Middle Aged
Prospective Studies
Pulmonary Disease, Chronic Obstructive / complications
Risk Factors
Vascular Diseases / complications
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment...
Next Document:  Imaging evaluation of demyelinating processes of the central nervous system.